Header Logo

Connection

RENE GONZALEZ to Middle Aged

Back to Details
This is a "connection" page, showing publications RENE GONZALEZ has written about Middle Aged.
RENE GONZALEZ
Connection Strength
0.690
Middle Aged
  1. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704.
    View in: PubMed
    Score: 0.029
  2. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236.
    View in: PubMed
    Score: 0.025
  3. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010 Jun; 20(3):218-26.
    View in: PubMed
    Score: 0.021
  4. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
    View in: PubMed
    Score: 0.021
  5. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2008 Feb; 26(1):89-94.
    View in: PubMed
    Score: 0.018
  6. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007 Oct; 14(10):2854-60.
    View in: PubMed
    Score: 0.018
  7. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res. 2006 Dec; 16(6):521-6.
    View in: PubMed
    Score: 0.017
  8. Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006 Aug 01; 94(2):101-4.
    View in: PubMed
    Score: 0.016
  9. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
    View in: PubMed
    Score: 0.016
  10. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan; 24(1):89-94.
    View in: PubMed
    Score: 0.016
  11. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005; 23(4):303-8.
    View in: PubMed
    Score: 0.015
  12. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. Int J Cancer. 2024 Nov 15; 155(10):1792-1807.
    View in: PubMed
    Score: 0.014
  13. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15; 130(10):1784-1796.
    View in: PubMed
    Score: 0.014
  14. A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma. Invest New Drugs. 2002 Aug; 20(3):357-62.
    View in: PubMed
    Score: 0.012
  15. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer. 2002 Jan 15; 94(2):470-6.
    View in: PubMed
    Score: 0.012
  16. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res. 2021 02 01; 31(1):67-75.
    View in: PubMed
    Score: 0.011
  17. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). J Clin Oncol. 2020 09 01; 38(25):2916-2925.
    View in: PubMed
    Score: 0.011
  18. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683.
    View in: PubMed
    Score: 0.011
  19. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
    View in: PubMed
    Score: 0.010
  20. A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. J Surg Oncol. 2019 Dec; 120(7):1276-1283.
    View in: PubMed
    Score: 0.010
  21. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
    View in: PubMed
    Score: 0.010
  22. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 10 17; 381(16):1535-1546.
    View in: PubMed
    Score: 0.010
  23. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019 04 10; 37(11):867-875.
    View in: PubMed
    Score: 0.010
  24. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 02 18; 7(1):49.
    View in: PubMed
    Score: 0.010
  25. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018 Oct; 63:282-291.
    View in: PubMed
    Score: 0.009
  26. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res. 2017 12; 27(6):585-590.
    View in: PubMed
    Score: 0.009
  27. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45.
    View in: PubMed
    Score: 0.009
  28. ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther. 2018 01; 17(1):222-231.
    View in: PubMed
    Score: 0.009
  29. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2018 03 01; 36(7):667-673.
    View in: PubMed
    Score: 0.009
  30. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 10 05; 377(14):1345-1356.
    View in: PubMed
    Score: 0.009
  31. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017 11 09; 377(19):1824-1835.
    View in: PubMed
    Score: 0.009
  32. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017 09; 82:80-91.
    View in: PubMed
    Score: 0.009
  33. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544.
    View in: PubMed
    Score: 0.008
  34. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun. 2016 Feb; 37(2):122-8.
    View in: PubMed
    Score: 0.008
  35. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8.
    View in: PubMed
    Score: 0.008
  36. Association of sentinel lymph node diameter with melanoma metastasis. Am J Surg. 2016 Aug; 212(2):315-20.
    View in: PubMed
    Score: 0.008
  37. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
    View in: PubMed
    Score: 0.008
  38. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul 02; 373(1):23-34.
    View in: PubMed
    Score: 0.008
  39. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
    View in: PubMed
    Score: 0.007
  40. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015 Jan 01; 21(1):175-83.
    View in: PubMed
    Score: 0.007
  41. A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma. Cancer Med. 2015 May; 4(5):643-50.
    View in: PubMed
    Score: 0.007
  42. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
    View in: PubMed
    Score: 0.007
  43. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
    View in: PubMed
    Score: 0.007
  44. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24.
    View in: PubMed
    Score: 0.007
  45. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):197-202.
    View in: PubMed
    Score: 0.007
  46. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.007
  47. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013 May; 148(5):456-61.
    View in: PubMed
    Score: 0.007
  48. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74.
    View in: PubMed
    Score: 0.007
  49. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9.
    View in: PubMed
    Score: 0.006
  50. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703.
    View in: PubMed
    Score: 0.006
  51. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9.
    View in: PubMed
    Score: 0.006
  52. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012 Jul; 4(7):679-86.
    View in: PubMed
    Score: 0.006
  53. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14.
    View in: PubMed
    Score: 0.006
  54. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15.
    View in: PubMed
    Score: 0.006
  55. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15; 17(24):7765-75.
    View in: PubMed
    Score: 0.006
  56. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 02; 364(22):2119-27.
    View in: PubMed
    Score: 0.006
  57. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34.
    View in: PubMed
    Score: 0.006
  58. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
    View in: PubMed
    Score: 0.006
  59. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug 01; 116(15):3683-91.
    View in: PubMed
    Score: 0.005
  60. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8):711-23.
    View in: PubMed
    Score: 0.005
  61. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010 Apr 15; 16(8):2402-8.
    View in: PubMed
    Score: 0.005
  62. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
    View in: PubMed
    Score: 0.005
  63. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol. 2009 Dec 20; 27(36):6207-12.
    View in: PubMed
    Score: 0.005
  64. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71.
    View in: PubMed
    Score: 0.005
  65. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009 Nov 10; 27(32):5452-8.
    View in: PubMed
    Score: 0.005
  66. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30.
    View in: PubMed
    Score: 0.005
  67. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.005
  68. The absent-minded professor: an unusual complication of melanoma. Oncology (Williston Park). 2008 Dec; 22(14):1609-14.
    View in: PubMed
    Score: 0.005
  69. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
    View in: PubMed
    Score: 0.005
  70. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006 Dec; 192(6):878-81.
    View in: PubMed
    Score: 0.004
  71. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 2006 Feb 15; 12(4):1137-43.
    View in: PubMed
    Score: 0.004
  72. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64.
    View in: PubMed
    Score: 0.004
  73. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol. 2005 Dec 10; 23(35):8992-9000.
    View in: PubMed
    Score: 0.004
  74. Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg. 2005 Jun; 40(6):988-92; discussion 992.
    View in: PubMed
    Score: 0.004
  75. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg. 2005 Jan; 140(1):85-9.
    View in: PubMed
    Score: 0.004
  76. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.